GB Sciences Inc
GB Sciences, Inc., a plant-based research and biopharmaceutical drug development company. The company offers cannabis inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, cytokine release syndrome, stress… Read more
GB Sciences Inc (GBLX) - Total Liabilities
Latest total liabilities as of June 2025: $5.97 Million USD
Based on the latest financial reports, GB Sciences Inc (GBLX) has total liabilities worth $5.97 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
GB Sciences Inc - Total Liabilities Trend (2003–2024)
This chart illustrates how GB Sciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
GB Sciences Inc Competitors by Total Liabilities
The table below lists competitors of GB Sciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Transition Evergreen
PA:EGR
|
France | €56.53 Million |
|
DOCCHECK N (AJ91.SG)
STU:AJ91
|
Germany | €18.11 Million |
|
Strata Power Corp
PINK:SPOWF
|
USA | $411.44K |
|
Decklar Resources Inc
PINK:DKLRF
|
USA | $32.64 Million |
|
ORIOR N (9OI.SG)
STU:9OI
|
Germany | €281.87 Million |
|
DOCCHECK N - Dusseldorf Stock Exchang
DU:AJ91
|
Germany | €18.11 Million |
Liability Composition Analysis (2003–2024)
This chart breaks down GB Sciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 63.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GB Sciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GB Sciences Inc (2003–2024)
The table below shows the annual total liabilities of GB Sciences Inc from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-03-31 | $5.42 Million | +13.82% |
| 2023-03-31 | $4.76 Million | +9.85% |
| 2022-03-31 | $4.33 Million | -64.72% |
| 2021-03-31 | $12.28 Million | -14.97% |
| 2020-03-31 | $14.44 Million | +12.23% |
| 2019-03-31 | $12.87 Million | +52.85% |
| 2018-03-31 | $8.42 Million | +82.91% |
| 2017-03-31 | $4.60 Million | +4.35% |
| 2016-03-31 | $4.41 Million | +265.96% |
| 2015-03-31 | $1.21 Million | -22.32% |
| 2014-03-31 | $1.55 Million | +29.68% |
| 2013-03-31 | $1.20 Million | -5.77% |
| 2012-03-31 | $1.27 Million | -10.58% |
| 2011-03-31 | $1.42 Million | +32.81% |
| 2010-03-31 | $1.07 Million | +196.93% |
| 2009-03-31 | $359.99K | +65.82% |
| 2008-03-31 | $217.10K | -61.12% |
| 2007-03-31 | $558.33K | +129.07% |
| 2006-03-31 | $243.74K | +832.68% |
| 2005-03-31 | $26.13K | -9.21% |
| 2004-03-31 | $28.79K | +1781.37% |
| 2003-03-31 | $1.53K | -- |